August 19, 2022 11:00 AM EDT
Coronavirus

Covid-19 roundup: EMA starts re­view of SK’s vac­cine; Aus­tralian biotech switch­ing gears away from Covid re­search

Tyler Patchen

News Reporter

An­oth­er Covid-19 vac­cine will en­ter the fray as the EMA kicks off its con­di­tion­al mar­ket­ing au­tho­riza­tion ap­pli­ca­tion for SK’s vac­cine, dubbed Sky­covion.

SK Chem­i­cals GmbH …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

A service from the Financial Times